CRISPR Therapeutics AG
CRSP
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.57B
Close$
$-0.48
100.9% downside
Current Fair Value
100.9% downsideOvervalued by 100.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.57 Billion |
|---|---|
| Enterprise Value | $6.07 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.47 |
| Beta | 1.74 |
| Outstanding Shares | 96,514,102 |
Return
| Return on Equity | -25.83% |
|---|---|
| Return on Assets | -17.02% |
| Return on Invested Capital | -20.08% |
Valuation & Multiples
| P/E Ratio | -12.13 |
|---|---|
| PEG | 21.54 |
| Price to Sales | - |
| Price to Book Ratio | 3.14 |
| Enterprise Value to Revenue | 453.6 |
| Enterprise Value to EBIT | -12.01 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 0.46 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-1.19
Average shareholder expectationRevenue Estimate
$7.45 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-1.06
Average shareholder expectationRevenue Estimate
$14.84 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9437▲ 10.58% |
|---|---|
| Total Calls | 1,312,000▼ 37.24% |
| Total Puts | 1,238,100▼ 29.31% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 86.02%▲ 5.70% |
|---|---|
| Total Invested | $4.31B▲ 17.47% |
| Investors Holding | 556▲ 30.00% |
ESG Score
No data
About CRISPR Therapeutics AG
CEO: Samarth Kulkarni